Skip to content

Study · Randomized controlled trial · 2025

6 results

Decreases in circulating ANGPTL3/8 concentrations following retatrutide treatment parallel reductions in serum lipids.

Wen Y, Lemen D, Lin Y, Chen YQ, Regmi A, Roell WC, Thomas MK, Hartman ML, Coskun T, Milicevic Z, Haupt A, Ruotolo G, Konrad RJ

Diabetes, obesity & metabolism29 Jul 2025Cited by 8 (Europe PMC)

PMID40726454 (opens in a new tab)PMCIDPMC12409240 (opens in a new tab)DOI10.1111/dom.16661 (opens in a new tab)PepBankPUB-40726454
Read at sourcePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialMechanism

    In participants with type 2 diabetes, retatrutide 8 and 12 mg reduced circulating ANGPTL3/8 concentrations.

    In plain wordsIn people with type 2 diabetes, retatrutide at 8 and 12 mg lowered blood levels of the ANGPTL3/8 complex.

    Peptide
    Retatrutide
    Outcome
    DecreaseCirculating ANGPTL3/8 in type 2 diabetes
    Study

    n: not reported in source

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    8 and 12 mgAs given in this study (human).

    Source sentences

    Summary
    ANGPTL3/8 reductions were observed with 8 and 12 mg retatrutide doses in participants with type 2 diabetes
    1 context sentence
    Summary · context
    In post-hoc analyses of two phase 2 retatrutide trials, concentrations of ANGPTL3/8, ANGPTL4/8 complex (ANGPTL4/8), ANGPTL3 and ANGPTL4 were measured using dedicated immunoassays to determine percent changes from baseline.
  2. 02HumanRandomized controlled trialMechanism

    In participants with obesity or overweight but without diabetes, retatrutide 1, 4, 8 and 12 mg reduced circulating ANGPTL3/8 concentrations.

    In plain wordsIn people with obesity or overweight and without diabetes, retatrutide at 1 to 12 mg lowered blood levels of the ANGPTL3/8 complex.

    Peptide
    Retatrutide
    Outcome
    DecreaseCirculating ANGPTL3/8 in obesity or overweight without diabetes
    Study

    n: not reported in source

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    1, 4, 8 and 12 mgAs given in this study (human).

    Source sentences

    Summary
    and with 1, 4, 8 and 12 mg retatrutide doses in participants with obesity or overweight but without diabetes.
    1 context sentence
    Summary · context
    In post-hoc analyses of two phase 2 retatrutide trials, concentrations of ANGPTL3/8, ANGPTL4/8 complex (ANGPTL4/8), ANGPTL3 and ANGPTL4 were measured using dedicated immunoassays to determine percent changes from baseline.
  3. 03HumanRandomized controlled trialMechanism

    In both trial populations, retatrutide reduced triglycerides, and the reduction paralleled the decrease in ANGPTL3/8.

    In plain wordsIn both trial groups, retatrutide lowered triglycerides, and this went together with lower ANGPTL3/8 levels.

    Peptide
    Retatrutide
    Outcome
    DecreaseTriglyceride reduction paralleling ANGPTL3/8 decrease
    Study

    n: not reported in source

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In both cases, ANGPTL3/8 decreases paralleled retatrutide-induced reductions in TG and LDL-C.
    1 context sentence
    Summary · context
    In post-hoc analyses of two phase 2 retatrutide trials, concentrations of ANGPTL3/8, ANGPTL4/8 complex (ANGPTL4/8), ANGPTL3 and ANGPTL4 were measured using dedicated immunoassays to determine percent changes from baseline.
  4. 04HumanRandomized controlled trialMechanism

    In both trial populations, retatrutide reduced LDL-C, and the reduction paralleled the decrease in ANGPTL3/8.

    In plain wordsIn both trial groups, retatrutide lowered LDL cholesterol, and this went together with lower ANGPTL3/8 levels.

    Peptide
    Retatrutide
    Outcome
    DecreaseLDL-C reduction paralleling ANGPTL3/8 decrease
    Study

    n: not reported in source

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In both cases, ANGPTL3/8 decreases paralleled retatrutide-induced reductions in TG and LDL-C.
    1 context sentence
    Summary · context
    In post-hoc analyses of two phase 2 retatrutide trials, concentrations of ANGPTL3/8, ANGPTL4/8 complex (ANGPTL4/8), ANGPTL3 and ANGPTL4 were measured using dedicated immunoassays to determine percent changes from baseline.
  5. 05LabIn vitro (cells)Mechanism

    In primary human hepatocytes, retatrutide decreased ANGPTL3/8 secretion.

    In plain wordsIn cells, retatrutide lowered the release of the ANGPTL3/8 complex from human liver cells.

    Peptide
    Retatrutide
    Outcome
    DecreaseANGPTL3/8 secretion from hepatocytes
    Study

    humann: not reported in source

    primary human hepatocytes
    Outcome group
    Receptor activity and mechanism · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In primary human hepatocytes, both glucagon and retatrutide decreased ANGPTL3/8 secretion
    1 context sentence
    Summary · context
    Direct effects of retatrutide itself, GIP, GLP-1, GCG and a GCG receptor (GCGR) antagonist antibody on ANGPTL3/8 secretion were studied in vitro using primary human hepatocytes.
  6. 06LabIn vitro (cells)Mechanism

    In primary human hepatocytes, the retatrutide-induced reduction in ANGPTL3/8 secretion was blocked by a GCGR antagonist antibody.

    In plain wordsIn cells, a glucagon receptor blocker stopped retatrutide from lowering ANGPTL3/8 release from human liver cells.

    Peptide
    Retatrutide
    Outcome
    No significant changeANGPTL3/8 secretion with GCGR antagonist antibody
    Study

    humann: not reported in source

    primary human hepatocytes
    Comparator
    GCGR antagonist antibody
    Outcome group
    Receptor activity and mechanism · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    and these reductions were blocked with the GCGR antagonist antibody.
    1 context sentence
    Summary · context
    Direct effects of retatrutide itself, GIP, GLP-1, GCG and a GCG receptor (GCGR) antagonist antibody on ANGPTL3/8 secretion were studied in vitro using primary human hepatocytes.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.